R. F. Bruns

发表

Species differences in affinities of non-peptide antagonists for substance P receptors.

J. Howbert, B. Gitter, D. C. Waters, 1991, European journal of pharmacology.

Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists.

P. Hipskind, S. Iyengar, D. Zimmerman, 1997, Journal of medicinal chemistry.

Synthesis and evaluation of a series of novel 2-[(4-chlorophenoxy)methyl]benzimidazoles as selective neuropeptide Y Y1 receptor antagonists.

P. Hipskind, P. Ornstein, B. Cantrell, 1998, Journal of medicinal chemistry.

The Neuropeptide Y Y1 Antagonist, 1229U91, A Potent Agonist for the Human Pancreatic Polypeptide-Preferring (NPY Y4) Receptor

D. Smiley, D. Gehlert, D. Schober, 1998, Peptides.

Structure-activity relationships of a series of 1-substituted-4-methylbenzimidazole neuropeptide Y-1 receptor antagonists.

P. Hipskind, P. Ornstein, B. Cantrell, 1998, Bioorganic & medicinal chemistry letters.

Structure-activity relationship of a series of diaminoalkyl substituted benzimidazole as neuropeptide Y Y1 receptor antagonists.

P. Hipskind, P. Ornstein, B. Cantrell, 1999, Bioorganic & medicinal chemistry letters.

Structure-activity relationships of a series of benzothiophene-derived NPY Y1 antagonists: optimization of the C-2 side chain.

P. Hipskind, D. Zimmerman, D. Gehlert, 1999, Bioorganic & medicinal chemistry letters.

Rapid parallel synthesis applied to the optimization of a series of potent nonpeptide neuropeptide Y-1 receptor antagonists

M. Siegel, P. Ornstein, M. Clay, 1999 .

Inhibition of protein kinase C by calphostin C is light-dependent.

J. Howbert, I. Takahashi, T. Tamaoki, 1991, Biochemical and biophysical research communications.

Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts.

R. F. Bruns, Robert F. Bruns, 1981, Biochemical pharmacology.

Subclasses of angiotensin II binding sites and their functional significance.

R. Panek, G. Lu, T. Major, 1990, Molecular pharmacology.

N6-bicycloalkyladenosines with unusually high potency and selectivity for the adenosine A1 receptor.

A. Bridges, B. K. Trivedi, R. F. Bruns, 1989, Journal of medicinal chemistry.

Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice

T. Heffner, R. F. Bruns, D. A. Downs, 2004, Psychopharmacology.

Characteristics of an adenosine A1 binding site in human placental membranes.

I. Fox, K. Hutchison, R. F. Bruns, 1989, Archives of biochemistry and biophysics.

Diphenylpyrazolidinone and benzodiazepine cholecystokinin antagonists: A case of convergent evolution in medicinal chemistry

J. Howbert, T. Britton, R. F. Bruns, 1993 .

PD 115,199: An antagonist ligand for adenosine A2 receptors

J. Fergus, S. Hays, R. F. Bruns, 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.

Role of Adenosine in Energy Supply/Demand Balance

R. F. Bruns, 1991 .

Functional activity of the adenosine binding enhancer, PD 81,723, in the in vitro hippocampal slice

R. Berman, R. F. Bruns, C. Janusz, 1991, Brain Research.

Structure-Activity Relationships of Adenosine A1 and A2 Receptors

A. Bridges, B. K. Trivedi, R. F. Bruns, 1990 .

Correlation of adenosine receptor affinities and cardiovascular activity.

H. W. Hamilton, M. Taylor, R. F. Bruns, 1987, Life sciences.

Nomenclature for excitatory amino acid receptors

R. F. Bruns, 1986, Trends in Neurosciences.

RECEPTORS FOR ADENOSINE AND ADENINE NUCLEOTIDES

R. F. Bruns, 1983 .

N6-substituted adenosine receptor agonists: potential antihypertensive agents.

C. J. Blankley, H. W. Hamilton, M. J. Ryan, 1991, Journal of medicinal chemistry.

Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist.

J. Howbert, P. Threlkeld, B. Gitter, 1995, The Journal of pharmacology and experimental therapeutics.

Azetidinones as vasopressin V1a antagonists.

C. Ferris, M. Brownstein, M. Clay, 2007, Bioorganic & medicinal chemistry.

Allosteric enhancer PD 81,723 acts by novel mechanism to potentiate cardiac actions of adenosine.

D. Dennis, J. Linden, L. Belardinelli, 1994, Circulation research.

Cardiac functional responses to adenosine by PD 81,723, an allosteric enhancer of the adenosine A1 receptor.

R. Vestal, R. F. Bruns, S. Montamat, 1993, The American journal of physiology.

Cyclosporin A is a substance P (tachykinin NK1) receptor antagonist.

P. Threlkeld, B. Gitter, D. C. Waters, 1995, European journal of pharmacology.

Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application.

H. W. Hamilton, D. Ortwine, R. F. Bruns, 1985, Journal of medicinal chemistry.

Adenosine receptor binding: structure-activity analysis generates extremely potent xanthine antagonists.

R. F. Bruns, J. W. Daly, S. H. Snyder, 1983, Proceedings of the National Academy of Sciences of the United States of America.

Binding of leukotrienes C4 and D4 to membranes from guinea pig lung: regulation by ions and guanine nucleotides.

W. Thomsen, T. Pugsley, R. F. Bruns, 1983, Life sciences.

A rapid filtration assay for soluble receptors using polyethylenimine-treated filters.

T. Pugsley, R. F. Bruns, K. Lawson-Wendling, 1983, Analytical biochemistry.

Evaluation and synthesis of aminohydroxyisoxazoles and pyrazoles as potential glycine agonists.

D. Ortwine, R. F. Bruns, J. Drummond, 1989, Journal of Medicinal Chemistry.

Multiple neurotransmitter receptors in the brain: amines, adenosine, and cholecystokinin.

S. Snyder, R. Innis, J. Daly, 1981, Federation proceedings.

Adenosine receptors in the central nervous system: relationship to the central actions of methylxanthines.

S H Snyder, S. Snyder, J. Daly, 1981, Life sciences.

Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes.

J. Fergus, R F Bruns, J H Fergus, 1990, Molecular pharmacology.

Linear and proximal benzo-separated alkylated xanthines as adenosine-receptor antagonists.

W. Christ, S. Schneller, R. F. Bruns, 1989, Journal of medicinal chemistry.

[1,2,4]Triazolo[4,3-a]quinoxalin-4-amines: a new class of A1 receptor selective adenosine antagonists.

B. K. Trivedi, R. F. Bruns, 1988, Journal of medicinal chemistry.

Evaluation and synthesis of aminohydroxyisoxazoles and pyrazoles as potential glycine agonists.

D. Ortwine, R. F. Bruns, J. Drummond, 1989, Journal of medicinal chemistry.

Glutamate- and veratridine-elicited accumulations of cyclic AMP in brain slices: a role for factors which potentiate adenosine-responsive systems

J. Daly, F. Pons, R. F. Bruns, 1980, Brain Research.

Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes.

G. Lu, T. Pugsley, R. F. Bruns, 1986, Molecular pharmacology.

N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.

W. Moos, R. F. Bruns, D. S. Szotek, 1985, Journal of medicinal chemistry.

Adenosine receptors in brain membranes: binding of N6-cyclohexyl[3H]adenosine and 1,3-diethyl-8-[3H]phenylxanthine.

S. Snyder, J. Daly, R. F. Bruns, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Adenosine Receptors

R. F. Bruns, 1990, Annals of the New York Academy of Sciences.

Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists.

R F Bruns, R. F. Bruns, 1980, Canadian journal of physiology and pharmacology.

Chapter 5. Central Nervous System Actions of Adenosine Agonists and Antagonists

T. Heffner, A. Bridges, R. F. Bruns, 1988 .

Depolarization‐Evoked Accumulation of Cyclic AMP in Brain Slices: The Requisite Intermediate Adenosine is Not Derived from Hydrolysis of Released ATP

J. Daly, F. Pons, R. F. Bruns, 1980, Journal of neurochemistry.

Adenosine receptors and behavioral actions of methylxanthines.

S H Snyder, S. Snyder, J. Daly, 1981, Proceedings of the National Academy of Sciences of the United States of America.

3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists.

J. Howbert, P. Hipskind, S. Iyengar, 1996, Journal of medicinal chemistry.

N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.

A. Bridges, D. Ortwine, B. K. Trivedi, 1988, Journal of medicinal chemistry.

Adenosine receptor activation by adenine nucleotides requires conversion of the nucleotides to adenosine

R. F. Bruns, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Purinergic Receptors, Past and Future (Closing Remarks)

R. F. Bruns, 1991 .

Synthesis and Pharmacological Characterization of 2-(2,6-dichlorophenyl)-1-((1S,3R)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (LY3154207), a potent, subtype selective, and orally available positive allosteric modulator of the human dopamine D1

G. Stephenson, Charles R. Yang, S. Mitchell, 2019, Journal of medicinal chemistry.

N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.

T. Heffner, A. Bridges, W. Moos, 1987, Journal of medicinal chemistry.

An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis

Todd R. Wiernicki, Charles R. Yang, T. Suter, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders.

K. Svensson, J. Hao, R. F. Bruns, 2019, Advances in pharmacology.

Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders

Hong Wang, Charles R. Yang, M. O'Neill, 2018, Neuropharmacology.

Rules for identifying potentially reactive or promiscuous compounds.

Ian A. Watson, Ian A Watson, Robert F Bruns, 2012, Journal of medicinal chemistry.

C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.

B. K. Trivedi, R. F. Bruns, Robert F. Bruns, 1989, Journal of medicinal chemistry.

PD 81,723, an allosteric enhancer of the A1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs.

J. Linden, J. Auchampach, J Linden, 1996, Circulation research.

Adenosine receptor interactions and anxiolytics

S. Snyder, J. Daly, R. F. Bruns, 1983, Neuropharmacology.

Adenosine Receptor Subtypes: Binding Studies

G. Lu, T. Pugsley, R. F. Bruns, 1987 .

Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes

James A. Bristol, Edward W. Badger, J. Fergus, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Structure Activity Relationships for Adenosine Antagonists

R. F. Bruns, 1990 .

Solubilities of Adenosine Antagonists Determined by Radioreceptor Assay

J. Fergus, R. F. Bruns, 1989, The Journal of pharmacy and pharmacology.

Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor

Charles R. Yang, Y. Qian, B. Heinz, 2018, Molecular Pharmacology.

Adenosine receptors in brain membranes : Binding of N 6-cyclohexyl [ 3 H ] adenosine and 1 , 3-diethyl-8-[ 3 H ] phenylxanthine ( methylxanthines / adenylate cyclase )

S. Snyder, R. F. Bruns, J. W. Dalyt, 2022 .

Effects of DPTQ, a novel positive allosteric modulator of the dopamine D1 receptor, on spontaneous eye blink rate and spatial working memory in the nonhuman primate

Graham V. Williams, S. Castner, H. Marston, 2023, Psychopharmacology.

N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.

B. K. Trivedi, R. F. Bruns, J. Bristol, 1988, Journal of Medicinal Chemistry.

Mutual Cooperativity of Three Allosteric Sites on the Dopamine D1 Receptor

F. Willard, E. Hembre, R. F. Bruns, 2022, Molecular Pharmacology.

Ribose-modified adenosine analogues as adenosine receptor agonists.

T. Heffner, H. W. Hamilton, M. Taylor, 1986, Journal of medicinal chemistry.

Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes.

J. Fergus, T. Pugsley, J. Dodd, 1990, Molecular pharmacology.

SYNTHESIS OF XANTHINES AS ADENOSINE ANTAGONISTS, A PRACTICAL QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP APPLICATION

H. W. Hamilton, D. Ortwine, R. F. Bruns, 1985 .

Conformational induction versus conformational selection: evidence from allosteric enhancers.

R. F. Bruns, 1996, Trends in pharmacological sciences.

N6-cyclohexyladenosine and 1,3-diethyl-8-phenylxanthine label two distinct adenosine receptors in brain membranes

J. Daly, R. F. Bruns, S. Snyder, 1980 .